Physician profile
John D Coble
NPI 1174507677
$2,332.07
in general payments reported to CMS, 2019-2025
15 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $336 · 2021: $329 · 2022: $171 · 2023: $647 · 2024: $359 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $629.12 | 2019-2023 | Acuvue |
| Bausch & Lomb Americas INC. | $567.30 | 2023-2025 | Infuse, Lotemax Sm, Vyzulta |
| Aerie Pharmaceuticals, INC. | $235.64 | 2019-2020 | |
| Allergan, INC. | $177.21 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $123.06 | 2019-2022 | |
| Lensar, INC. | $122.39 | 2025 | Lensar Laser System |
| Harrow Eye, LLC | $120.40 | 2024 | Vevye |
| Abbvie INC. | $76.90 | 2023 | Vuity, Lumigan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $71.06 | 2019-2021 | |
| Oyster Point Pharma, INC. | $54.79 | 2023-2024 | Tyrvaya, Ryzumvi |
| Shire North American Group INC | $48.38 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $35.17 | 2025 | Xdemvy |
| Alcon Vision LLC | $33.28 | 2023-2025 | Precision7, Precision 1 |
| Dompe US, INC. | $26.19 | 2025 | Oxervate |
| Lkc Technologies, INC. | $11.18 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Coble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.